The U.S. Food and Drug Administration (FDA) has accepted United Therapeutics’ application for a priority review of Tyvaso DPI, an experimental dry powder inhaled formulation of treprostinil, to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). …
Following my idiopathic pulmonary fibrosis (IPF) diagnosis in 2016, I had many fears. As an avid traveler, my No. 1 fear was being put on supplemental oxygen and losing the ability to fly. I also feared that using oxygen would prevent me from partaking in many of the outdoor…
Those who wish to gain practical tools for living optimally with rare diseases are encouraged to attend the annual Living Rare Living Stronger Patient and Family Forum, hosted by the National Organization for Rare Disorders (NORD) and set this year for June 26-27. The conference brings together patients,…
Scientists found that mesenchymal stromal cells (MSCs) — cells that have similar properties to stem cells — individually coated with a soft microgel were able to reverse established lung tissue scarring in a mouse model of pulmonary fibrosis. Their findings were reported in…
After my idiopathic pulmonary fibrosis (IPF) diagnosis, I was in denial about having the disease. So, I had a video-assisted thoracoscopic lung biopsy in July 2014. The pathologist said my diagnosis was “fibrosing and interstitial…
Nuformix announced it has received notice that it can expect to be granted a U.S. patent for its potential inhaled therapy for idiopathic pulmonary fibrosis (IPF). NXP002, the company’s lead pre-clinical asset, is a new formulation of tranilast, an antiallergic medication that is under investigation for its…
Adding two broad spectrum antibiotics — co-trimoxazole or doxycycline — to standard care does not significantly delay hospitalization or prolong survival in adults with idiopathic pulmonary fibrosis (IPF), according to data from one of the largest clinical trials in IPF. While several studies have shown that changes in lung…
If I asked you to identify yourself, what would you say? “My name is …” “I am a …” “I work as a …” “I was born in …” There are an infinite number of ways to define and describe ourselves. If each facet of our personality were an ID…
Esbriet (pirfenidone) appears to slow the progression of idiopathic pulmonary fibrosis (IPF) regardless of the presence of autoantibodies, which might mean the therapy can work even when IPF is linked to an autoimmune disease, a study suggests. The study, “Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according…
According to the Canadian Lung Association, idiopathic pulmonary fibrosis (IPF) is difficult to diagnose because its symptoms mimic other common respiratory conditions. I have spoken with many IPF patients who can attest to this. They describe their diagnostic journey as long, complicated, and frustrating. The process of being diagnosed…
Get regular updates to your inbox.
